Current Report Filing (8-k)
November 08 2022 - 8:53AM
Edgar (US Regulatory)
0001811623
false
0001811623
2022-11-08
2022-11-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 8, 2022
PaxMedica, Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-41475 |
|
85-0870387 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
303 South Broadway, Suite 125
Tarrytown, NY |
|
10591 |
(Address of principal executive offices) |
|
(Zip Code) |
(914) 987-2876
(Registrant’s telephone number, including
area code)
n/a
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2.
below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
Common Stock, par value $0.0001 per share |
|
PXMD |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 8.01 Other Events
On November 8, 2022, PaxMedica, Inc. issued
a press release announcing the initiation of its clinical program to advance PAX-101 towards FDA submission.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PaxMedica, Inc. |
|
|
|
|
By: |
/s/ Howard J. Weisman |
|
Name: |
Howard J. Weisman |
|
Title: |
Chief Executive Officer |
Date: November 8, 2022
PaxMedica (NASDAQ:PXMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
PaxMedica (NASDAQ:PXMD)
Historical Stock Chart
From Sep 2023 to Sep 2024